CRIS Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -344.32% compared to Curis's net margin of --. Curis's return on equity of -461.34% beat Armata Pharmaceuticals's return on equity of --.

Curis has a consensus price target of $16.00, signalling upside risk potential of 881.6%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 392.96%. Given that Curis has higher upside potential than Armata Pharmaceuticals, analysts believe Curis is more attractive than Armata Pharmaceuticals.

Curis has a beta of 3.511, which suggesting that the stock is 251.058% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.595%.

Curis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Curis quarterly revenues are $2.9M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Curis's net income of -$10.1M is lower than Armata Pharmaceuticals's net income of $2.6M. Notably, Curis's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis is 0.94x versus 514.70x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -344.32% compared to Curis's net margin of --. Curis's return on equity of -461.34% beat Perspective Therapeutics's return on equity of --.

Curis has a consensus price target of $16.00, signalling upside risk potential of 881.6%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 502.21%. Given that Curis has higher upside potential than Perspective Therapeutics, analysts believe Curis is more attractive than Perspective Therapeutics.

Curis has a beta of 3.511, which suggesting that the stock is 251.058% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Curis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Curis quarterly revenues are $2.9M, which are larger than Perspective Therapeutics quarterly revenues of --. Curis's net income of -$10.1M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Curis's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis is 0.94x versus 15.47x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -344.32% compared to Curis's net margin of 12.11%. Curis's return on equity of -461.34% beat Electromed's return on equity of 15.91%.

Curis has a consensus price target of $16.00, signalling upside risk potential of 881.6%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 60.45%. Given that Curis has higher upside potential than Electromed, analysts believe Curis is more attractive than Electromed.

Curis has a beta of 3.511, which suggesting that the stock is 251.058% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Curis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Curis quarterly revenues are $2.9M, which are smaller than Electromed quarterly revenues of $16.3M. Curis's net income of -$10.1M is lower than Electromed's net income of $2M. Notably, Curis's price-to-earnings ratio is -- while Electromed's PE ratio is 30.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis is 0.94x versus 3.46x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -344.32% compared to Curis's net margin of 35.65%. Curis's return on equity of -461.34% beat Protalix BioTherapeutics's return on equity of 8.75%.

Curis has a consensus price target of $16.00, signalling upside risk potential of 881.6%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 408.77%. Given that Curis has higher upside potential than Protalix BioTherapeutics, analysts believe Curis is more attractive than Protalix BioTherapeutics.

Curis has a beta of 3.511, which suggesting that the stock is 251.058% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Curis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Curis quarterly revenues are $2.9M, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Curis's net income of -$10.1M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Curis's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 95.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis is 0.94x versus 4.43x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.